CTLA4 and cancer: The evaluation of the possible use of antagonistic antibodies against CTLA–4 (as ipilimumab, the first approved immune checkpoint blockade drug) is ongoing, in order to inhibit the immune system tolerance to tumors, in this way possibly supplying a useful immunotherapy strategy for patients with cancer.